Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Associated Therapies: -

Clinical Trials

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Conditions: Therapeutic Drug Monitoring
Subarachnoid Hemorrhage
Intracerebral Hemorrhage

First Posted Date: 2019-10-18

Last Posted Date: 2021-07-21

Lead Sponsor: Azienda Sanitaria-Universitaria Integrata di Udine

Target Recruit Count: 104

Registration Number: NCT04132115

Locations: 🇮🇹
Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy
🇮🇹
Terapia Intensiva 1, Udine, Italy

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Phase 3

Terminated

Conditions: Surgical Site Infection

Interventions: Drug: Delafloxacin
Drug: Vancomycin
Drug: Linezolid
Drug: Piperacillin/Tazobactam
Drug: Tigecycline

First Posted Date: 2019-08-01

Last Posted Date: 2022-02-02

Lead Sponsor: Menarini Group

Target Recruit Count: 268

Registration Number: NCT04042077

Locations: 🇮🇹
Hospital Agostino Gemelli, Roma, Italy

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

Phase 2

Withdrawn

Conditions: Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma

Interventions: Drug: vancomycin

First Posted Date: 2019-07-19

Last Posted Date: 2020-03-16

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04025567

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion

Phase 2

Recruiting

Conditions: Surgical Site Infection

Interventions: Drug: Vancomycin

First Posted Date: 2019-07-12

Last Posted Date: 2024-05-01

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 450

Registration Number: NCT04017468

Locations: 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Saint Gallen, Switzerland
🇨🇭
University Hostpital Bern, Department of Neurosurgery, Bern, Switzerland
🇨🇭
University Hostpital Bern, Department of orthopaedy, Bern, Switzerland

and more 5 locations

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Phase 2

Completed

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Gram-Positive Bacterial Infections

Interventions: Drug: TNP-2092
Drug: Vancomycin

First Posted Date: 2019-05-28

Last Posted Date: 2023-12-01

Lead Sponsor: TenNor Therapeutics Limited

Target Recruit Count: 120

Registration Number: NCT03964493

Locations: 🇺🇸
eStudy Site, San Diego, California, United States

A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin

Not Applicable

Completed

Conditions: Human Microbiome

Interventions: Drug: Metformin (part 2)
Drug: Metformin (part 1)
Drug: Vancomycin

First Posted Date: 2019-01-18

Last Posted Date: 2020-10-08

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 20

Registration Number: NCT03809260

Locations: 🇰🇷
SNUBH Clinical trial centor, Seongnam-si, Gyeonggi-do, Korea, Republic of

The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level

Completed

Conditions: Vancomycin

First Posted Date: 2019-01-16

Last Posted Date: 2019-01-16

Lead Sponsor: Southeast University, China

Target Recruit Count: 165

Registration Number: NCT03806543

Fecal Transplantation for Primary Clostridium Difficile Infection

Phase 3

Conditions: Clostridium Difficile Infection

Interventions: Other: Fecal microbiota transplantation
Drug: Vancomycin

First Posted Date: 2019-01-08

Last Posted Date: 2022-04-29

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 188

Registration Number: NCT03796650

Locations: 🇳🇴
Sørlandet Hospital HF, Kristiansand, Norway
🇳🇴
Sykehuset i Vestfold, Tønsberg, Norway
🇳🇴
Sykehuset Levanger, Levanger, Norway

and more 15 locations

Placement of Antibiotic Powder in Wounds During the Emergency Room

Phase 4

Recruiting

Conditions: Open Fracture

Interventions: Drug: Vancomycin

First Posted Date: 2018-12-05

Last Posted Date: 2024-07-29

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 200

Registration Number: NCT03765567

Locations: 🇺🇸
University Hospital, San Antonio, Texas, United States
🇺🇸
San Antonio Military Medical Center, San Antonio, Texas, United States

Vancomycin for Primary Sclerosing Cholangitis

Phase 2

Active, not recruiting

Conditions: Primary Sclerosing Cholangitis

Interventions: Other: Placebo
Drug: Vancomycin

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-01

Lead Sponsor: Elizabeth Carey

Target Recruit Count: 102

Registration Number: NCT03710122

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Arizona State University, Tempe, Arizona, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy